



Amended Claims (Attorney Docket No. BHC 032009)

1. (Currently amended) A bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



wherein

A represents



wherein

Q₁ and Q₄ independently represent direct bond or methylene;

Q₂ represents CHR² or CO,

Q₃ represents CHR³ or CO,

wherein

R² represents hydrogen, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy, or C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy or mono-, di-, or tri- halogen;

R³ represents hydrogen, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy, or C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that

Q₁ and Q₄ can not be direct bond at the same time;

R^2 and R^3 can not be hydrogen at the same time;

when Q_1 represents direct bond,

R^3 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_5 represents CH or CR^5 ,

wherein

R^5 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy,
 C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

Q_6 represents CH or CR^6 ,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy,
 C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that Q_5 and Q_6 can not be CH at the same time;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond; and

-Y- represents CH_2 , O or NH; and

R¹ represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl, sulfonamide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl {wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen},

C₁₋₆ alkoxy {wherein said alkoxy is optionally substituted by mono-, di-, or tri-halogen},

C₁₋₆ alkylthio {wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen},


phenyl, benzyl and phenoxy ,

{wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈cycloalkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆alkoxycarbonyl or C₁₋₆ alkyl}.

2. (Currently amended) The bicyclic amide, carbamate or urea derivative of ~~the~~ formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q_1 and Q_4 represent methylene;

Q_2 represents CHR^2 or CO ,

wherein

R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_3 represents CHR^3 or CO ,

wherein

R^3 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_5 represents CH ;

Q_6 represents CR^6 ,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

$-\text{X}-$ represents a bond, $-\text{O}-$ or $-\text{N}(\text{R}^4)-$,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH₂, O or NH; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl, sulfonamide, C₁₋₆alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆alkyl-carbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl {wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen},

C₁₋₆ alkoxy {wherein said alkoxy is optionally substituted by mono-, di-, or tri-halogen},

C₁₋₆ alkylthio {wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen},


phenyl, benzyl and phenoxy ,

{wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl}.

3. (Currently amended) The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q_1 represents methylene;

Q_4 represents direct bond;

Q_2 represents CHR^2 or CO,

wherein

R^2 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_3 represents CHR^3 ,

wherein

R^3 represents hydrogen;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2 , O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen,

nitro, hydroxy, carboxy, cyano, amino, N-(C₁₋₆alkyl)amino,
 N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl,
 sulfonamide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl,
 C₁₋₆ alkylcarbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl {wherein said alkyl is optionally substituted by cyano, nitro, hydroxy,
 carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen},

C₁₋₆ alkoxy {wherein said alkoxy is optionally substituted by mono-, di-, or tri-
 halogen},

C₁₋₆ alkylthio {wherein said alkylthio is optionally substituted by mono-, di-, or
 tri- halogen},


phenyl, benzyl and phenoxy ,

{wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety
 of said phenoxy are optionally substituted by halogen, nitro, hydroxy,
 carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino,
 N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonyl or
 C₁₋₆ alkyl}.

4. (Currently amended) The bicyclic amide, carbamate or urea derivative of ~~the~~ formula (I), its
 tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₁ and Q₄ represents methylene;

Q₂ represents CHR²,

wherein

R^2 represents hydrogen;

Q_3 represents CHR^3 ,

wherein

R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein R^4 is hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2 , O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6} alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6} alkoxycarbonyl, sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6} alkanoyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl, C_{3-8} cycloalkyl, heterocycle,

C_{1-6} alkyl {wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen},

C_{1-6} alkoxy {wherein said alkoxy is optionally substituted by mono-, di-, or tri-halogen},

C₁₋₆ alkylthio {wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen},


phenyl, benzyl and phenoxy ,

{wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkyl}.

5. (Currently amended) The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₁ and Q₄ represent methylene;

Q₂ represents CHR²,

wherein

R² represents hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

Q₃ represents CHR³,

wherein

R³ represents hydrogen;

m represents an integer from 1 to 3;

p represents 0 or 1;

-X- represents a bond, -O- or -N(R⁴)-,

wherein

R⁴ is hydrogen or C₁₋₆ alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH₂, O or NH; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈ cycloalkyl)amino, C₁₋₆alkoxycarbonyl, sulfonamide, C₁₋₆ alkanoyl, N-(C₁₋₆alkanoyl)amino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₃₋₈cycloalkyl, heterocycle,

C₁₋₆ alkyl {wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen},

C₁₋₆ alkoxy {wherein said alkoxy is optionally substituted by mono-, di-, or tri-halogen},

C₁₋₆ alkylthio {wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen},

phenyl, benzyl and phenoxy ,


{wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy,

carboxy, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(C₃₋₈cycloalkyl)amino, C₁₋₆alkoxycarbonyl, C₁₋₆alkoxycarbonyl or C₁₋₆alkyl}.

6. (Currently amended) The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₅ represents CH;

Q₆ represent CR⁶,

wherein

R⁶ represents hydroxy, C₁₋₆alkoxy, C₁₋₆alkanoyloxy, or C₁₋₆alkyl optionally substituted by hydroxy, C₁₋₆alkoxy or C₁₋₆alkanoyloxy;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R⁴)-,

wherein

R⁴ represents hydrogen or C₁₋₆alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents NH, O or CH₂; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,


wherein

said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of halogen, nitro, C₁₋₆alkyl, trifluoroC₁₋₆alkyl, C₁₋₆alkoxy, trifluoroC₁₋₆alkoxy and C₁₋₆alkanoylamino.

7. (Currently amended) The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



Q₁ and Q₄ represents methylene;

Q₂ represents CHR²,

wherein

R² represents hydrogen;

Q₃ represents CHR³,

wherein

R³ represents hydrogen, hydroxy, C₁₋₆alkoxy or C₁₋₆alkanoyloxy;

Q₅ represents CH;

Q₆ represents CR⁶,

wherein

R⁶ represents hydroxy;

m represents an integer 2;

p represents an integer 0;

-X- represents a bond, -O- or -N(R⁴)-,

wherein

R⁴ is hydrogen or C₁₋₆ alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents NH or O; and

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methyl, methoxy, trifluoromethyl, trifluoroethyl, trifluoromethoxy, trifluoroethoxy, acetamido and propionylamino;

8. (Currently amended) The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said bicyclic amide, carbamate or urea derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[4-(trifluoromethyl)benzyl]urea;

4-(trifluoromethyl)benzyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-3-[4-(trifluoromethyl)phenyl]propanamide;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-(2-{[4-(trifluoromethyl)phenyl]-amino}ethyl)urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-(2-[4-(trifluoromethyl)phenoxy]ethyl)urea;

2-([4-(trifluoromethyl)phenyl]amino)ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

2-[4-(trifluoromethyl)phenoxy]ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate; and

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-(2-([4-chloro-3-(trifluoromethyl)phenyl]amino)ethyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-(2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-(2-([4-chloro-3-(trifluoromethyl)phenyl]amino)ethyl)-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea; and

N-(2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl)-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea.

9. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising ~~the~~ a bicyclic amide, carbamate or urea derivative of ~~the~~ formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
10. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 9, further comprising one or more pharmaceutically acceptable excipients.
11. (Currently amended) The ~~medicament~~ pharmaceutical composition as claimed in claim 9, wherein said bicyclic amide, carbamate or urea derivative of ~~the~~ formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
12. (Currently amended) ~~The medicament as claimed in claim 9~~ A method for the treatment and/or prevention of an urological disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of at least one bicyclic amide, carbamate or urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.

13. (Currently amended) The ~~medicament~~ method as claimed in claim 12, wherein said urological disorder or disease is urge urinary incontinence or overactive bladder.
14. (Currently amended) ~~The medicament as claimed in claim 9~~ A method for the treatment and/or prevention of pain comprising administering to a subject in need thereof a therapeutically effective amount of at least one bicyclic amide, carbamate or urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
15. (Currently amended) The ~~medicament~~ method as claimed in claim 14, wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
16. (Currently amended) ~~The medicament as claimed in claim 9~~ A method for the treatment and/or prevention of a disorder or disease related to pain comprising administering to a subject in need thereof a therapeutically effective amount of at least one bicyclic amide, carbamate or urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
17. (Currently amended) The ~~medicament~~ method as claimed in claim 16, wherein said disorder or disease related to pain is neuralgia, neuropathies, algasia, nerve injury, ischaemia, neurodegeneration, or stroke.
18. (Currently amended) ~~The medicament as claimed in claim 9~~ A method for the treatment and/or prevention of an inflammatory disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of at least one bicyclic amide, carbamate or urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
19. (Currently amended) The ~~medicament~~ method as claimed in claim 18, wherein said inflammatory disorder or disease is asthma or COPD.
20. (Cancelled).
21. (Cancelled).
22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).